Document is current
Any future updates will be listed below
-
Authors
Stepien, Karolina M.
Gevorkyan, Anait K.
Hendriksz, Christian J.
Lobzhanidze, Tinatin V.
Pérez-López, Jordi
Tol, Govind
del Toro Riera, Mireia
Vashakmadze, Nato D.
Lampe, Christina
- License Information
-
More Information
Article History
Received: 17 December 2019
Accepted: 13 April 2020
First Online: 14 May 2020
Ethics approval and consent to participate
: Not required.
: Not applicable.
: CJH is owner and CEO of FYMCA Medical Ltd. and Chief Medical Officer of and a shareholder in RareMD. CL has been a board member for BioMarin, Alexion, Shire and Genzyme; and received consultancy fees and grants from BioMarin and Shire, and payments for lectures from BioMarin, Alexion, Shire, Genzyme and Actelion. CL has also received travel, accommodation and meeting expenses from BioMarin, Alexion, Shire, Genzyme and Actelion. KMS has received travel grants from BioMarin, Genzyme, Alexion, Takeda and Chiesi, and attended advisory boards for Chiesi, Genzyme and Takeda.
